Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Arch Microbiol ; 204(8): 526, 2022 Jul 27.
Artículo en Inglés | MEDLINE | ID: mdl-35895237

RESUMEN

Viral infections are linked to a variety of human diseases. Despite the achievements made in drug and vaccine development, several viruses still lack preventive vaccines and efficient antiviral compounds. Thus, developing novel antiviral agents is of great concern, particularly the natural products that are promising candidates for such discoveries. In this study, we have purified an approximately 15 kDa basic phospholipase A2 (PLA2) enzyme from the Egyptian cobra Naja haje haje venom. The purified N. haje PLA2 showed a specific activity of 22 units/mg protein against 6 units/mg protein for the whole crude venom with 3.67-fold purification. The antiviral activity of purified N. haje PLA2 has been investigated in vitro against bovine coronavirus (BCoV) and simian rotavirus (RV SA-11). Our results showed that the CC50 of PLA2 were 33.6 and 29 µg/ml against MDBK and MA104 cell lines, respectively. Antiviral analysis of N. haje PLA2 showed an inhibition of BCoV and RV SA-11 infections with a therapeutic index equal to 33.6 and 16, respectively. Moreover, N. haje PLA2 decreased the BCoV and RV SA-11 titers by 4.25 log10 TCID50 and 2.5 log10 TCID50, respectively. Thus, this research suggests the potential antiviral activity of purified N. haje PLA2 against BCoV and RV SA-11 infections in vitro.


Asunto(s)
Antivirales , Coronavirus Bovino , Venenos Elapídicos , Fosfolipasas A2 , Rotavirus , Animales , Antivirales/farmacología , Coronavirus Bovino/efectos de los fármacos , Venenos Elapídicos/farmacología , Naja haje , Fosfolipasas A2/farmacología , Rotavirus/efectos de los fármacos
2.
Viruses ; 14(2)2022 02 17.
Artículo en Inglés | MEDLINE | ID: mdl-35216006

RESUMEN

Coronaviruses (CoVs) are common among humans and many animals, causing respiratory or gastrointestinal diseases. Currently, only a few antiviral drugs against CoVs are available. Especially for SARS-CoV-2, new compounds for treatment of COVID-19 are urgently needed. In this study, we characterize the antiviral effects of two high-sulfated glycosaminoglycan (GAG) derivatives against SARS-CoV-2 and bovine coronaviruses (BCoV), which are both members of the Betacoronavirus genus. The investigated compounds are based on hyaluronan (HA) and chondroitin sulfate (CS) and exhibit a strong inhibitory effect against both CoVs. Yield assays were performed using BCoV-infected PT cells in the presence and absence of the compounds. While the high-sulfated HA (sHA3) led to an inhibition of viral growth early after infection, high-sulfated CS (sCS3) had a slightly smaller effect. Time of addition assays, where sHA3 and sCS3 were added to PT cells before, during or after infection, demonstrated an inhibitory effect during all phases of infection, whereas sHA3 showed a stronger effect even after virus absorbance. Furthermore, attachment analyses with prechilled PT cells revealed that virus attachment is not blocked. In addition, sHA3 and sCS3 inactivated BCoV by stable binding. Analysis by quantitative real-time RT PCR underlines the high potency of the inhibitors against BCoV, as well as B.1-lineage, Alpha and Beta SARS-CoV-2 viruses. Taken together, these results demonstrated that the two high-sulfated GAG derivatives exhibit low cytotoxicity and represent promising candidates for an anti-CoV therapy.


Asunto(s)
Antivirales/farmacología , Infecciones por Coronavirus/veterinaria , Coronavirus Bovino/efectos de los fármacos , Glicosaminoglicanos/farmacología , SARS-CoV-2/efectos de los fármacos , Animales , Bovinos , Línea Celular , Sulfatos de Condroitina/química , Sulfatos de Condroitina/farmacología , Infecciones por Coronavirus/tratamiento farmacológico , Glicosaminoglicanos/química , Glicosaminoglicanos/metabolismo , Humanos , Ácido Hialurónico/química , Ácido Hialurónico/farmacología , Sulfatos/química , Sulfatos/farmacología , Acoplamiento Viral/efectos de los fármacos , Tratamiento Farmacológico de COVID-19
3.
J Hosp Infect ; 112: 108-113, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33864891

RESUMEN

BACKGROUND: The presence of coronaviruses on surfaces in the patient environment is a potential source of indirect transmission. Manual cleaning and disinfection measures do not always achieve sufficient removal of surface contamination. This increases the importance of automated solutions in the context of final disinfection of rooms in the hospital setting. Ozone is a highly effective disinfectant which, combined with high humidity, is an effective agent against respiratory viruses. Current devices allow continuous nebulization for high room humidity as well as ozone production without any consumables. AIM: In the following study, the effectiveness of a fully automatic room decontamination system based on ozone was tested against bacteriophage Φ6 (phi 6) and bovine coronavirus L9, as surrogate viruses for the pandemic coronavirus SARS-CoV-2. METHODS: For this purpose, various surfaces (ceramic tile, stainless steel surface and furniture board) were soiled with the surrogate viruses and placed at two different levels in a gas-tight test room. After using the automatic decontamination device according to the manufacturer's instructions, the surrogate viruses were recovered from the surfaces and examined by quantitative cultures. Then, reduction factors were calculated. FINDINGS: The ozone-based room decontamination device achieved virucidal efficacy (reduction factor >4 log10) against both surrogate organisms regardless of the different surfaces and positions confirming a high activity under the used conditions. CONCLUSION: Ozone is highly active against SARS-CoV-2 surrogate organisms. Further investigations are necessary for a safe application and efficacy in practice as well as integration into routine processes.


Asunto(s)
Automatización/instrumentación , COVID-19/prevención & control , Desinfectantes/farmacología , Desinfección/instrumentación , Desinfección/métodos , Ozono/farmacología , Animales , Bacteriófagos/efectos de los fármacos , COVID-19/transmisión , Bovinos , Coronavirus Bovino/efectos de los fármacos , Infección Hospitalaria/prevención & control , Infección Hospitalaria/virología , Descontaminación/instrumentación , Descontaminación/métodos , Equipos y Suministros de Hospitales/virología , Hospitales , Humanos , SARS-CoV-2/efectos de los fármacos
4.
Int J Nanomedicine ; 16: 1789-1804, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33688191

RESUMEN

BACKGROUND: SARS-COVID-2 has recently been one of the most life-threatening problems which urgently needs new therapeutic antiviral agents, especially those of herbal origin. PURPOSE: The study aimed to load acaciin (ACA) into the new self-assembled nanofibers (NFs) followed by investigating their possible antiviral effect against bovine coronavirus (BCV) as a surrogate model for SARS-COV-2. METHODS: ACA was identified using 1H-NMR and DEPT-Q 13C-NMR spectroscopy, the molecular docking study was performed using Autodock 4 and a modification of the traditional solvent injection method was applied for the synthesis of the biodegradable NFs. Different characterization techniques were used to inspect the formation of the NFs, which is followed by antiviral investigation against BCV as well as MTT assay using MDBK cells. RESULTS: Core/shell NFs, ranging between 80-330 nm with tiny thorn-like branches, were formed which attained an enhanced encapsulation efficiency (97.5 ± 0.53%, P<0.05) and a dual controlled release (a burst release of 65% at 1 h and a sustained release up to >24 h). The antiviral investigation of the formed NFs revealed a significant inhibition of 98.88 ± 0.16% (P<0.05) with IC50 of 12.6 µM against BCV cells. CONCLUSION: The results introduced a new, time/cost-saving strategy for the synthesis of biodegradable NFs without the need for electric current or hazardous cross-linking agents. Moreover, it provided an innovative avenue for the discovery of drugs of herbal origin for the fight against SARS-CoV-2 infection.


Asunto(s)
Coronavirus Bovino/efectos de los fármacos , Glicósidos/farmacología , Nanofibras/química , SARS-CoV-2/efectos de los fármacos , Antivirales/química , Antivirales/farmacología , COVID-19/virología , Línea Celular , Glicósidos/química , Glicósidos/aislamiento & purificación , Glicósidos/uso terapéutico , Humanos , Ligandos , Modelos Biológicos , Simulación del Acoplamiento Molecular , Nanofibras/ultraestructura , Solventes , Rayos Ultravioleta , Tratamiento Farmacológico de COVID-19
5.
Viruses ; 13(2)2021 02 20.
Artículo en Inglés | MEDLINE | ID: mdl-33672561

RESUMEN

In the face of new emerging respiratory viruses, such as SARS-CoV2, vaccines and drug therapies are not immediately available to curb the spread of infection. Non-pharmaceutical interventions, such as mask-wearing and social distance, can slow the transmission. However, both mask and social distance have not prevented the spread of respiratory viruses SARS-CoV2 within the US. There is an urgent need to develop an intervention that could reduce the spread of respiratory viruses. The key to preventing transmission is to eliminate the emission of SARS-CoV2 from an infected person and stop the virus from propagating in the human population. Rhamnolipids are environmentally friendly surfactants that are less toxic than the synthetic surfactants. In this study, rhamnolipid products, 222B, were investigated as disinfectants against enveloped viruses, such as bovine coronavirus and herpes simplex virus 1 (HSV-1). The 222B at 0.009% and 0.0045% completely inactivated 6 and 4 log PFU/mL of HSV-1 in 5-10 min, respectively. 222B at or below 0.005% is also biologically safe. Moreover, 50 µL of 222B at 0.005% on ~1 cm2 mask fabrics or plastic surface can inactivate ~103 PFU HSV-1 in 3-5 min. These results suggest that 222B coated on masks or plastic surface can reduce the emission of SARS-CoV2 from an infected person and stop the spread of SARS-CoV2.


Asunto(s)
COVID-19 , Coronavirus Bovino/efectos de los fármacos , Desinfectantes/farmacología , Glucolípidos/farmacología , Herpesvirus Humano 1/efectos de los fármacos , Tensoactivos/farmacología , COVID-19/prevención & control , COVID-19/transmisión , Humanos
6.
Sci Rep ; 10(1): 16631, 2020 10 06.
Artículo en Inglés | MEDLINE | ID: mdl-33024252

RESUMEN

The aim of this study was to test in vitro the ability of a mixture of citrus extract, maltodextrin, sodium chloride, lactic acid and citric acid (AuraShield L) to inhibit the virulence of infectious bronchitis, Newcastle disease, avian influenza, porcine reproductive and respiratory syndrome (PRRS) and bovine coronavirus viruses. Secondly, in vivo, we have investigated its efficacy against infectious bronchitis using a broiler infection model. In vitro, these antimicrobials had expressed antiviral activity against all five viruses through all phases of the infection process of the host cells. In vivo, the antimicrobial mixture reduced the virus load in the tracheal and lung tissue and significantly reduced the clinical signs of infection and the mortality rate in the experimental group E2 receiving AuraShield L. All these effects were accompanied by a significant reduction in the levels of pro-inflammatory cytokines and an increase in IgA levels and short chain fatty acids (SCFAs) in both trachea and lungs. Our study demonstrated that mixtures of natural antimicrobials, such AuraShield L, can prevent in vitro viral infection of cell cultures. Secondly, in vivo, the efficiency of vaccination was improved by preventing secondary viral infections through a mechanism involving significant increases in SCFA production and increased IgA levels. As a consequence the clinical signs of secondary infections were significantly reduced resulting in recovered production performance and lower mortality rates in the experimental group E2.


Asunto(s)
Antivirales/farmacología , Infecciones por Coronavirus/tratamiento farmacológico , Coronavirus Bovino/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Virus de la Bronquitis Infecciosa/efectos de los fármacos , Subtipo H9N2 del Virus de la Influenza A/efectos de los fármacos , Virus de la Enfermedad de Newcastle/efectos de los fármacos , Virus del Síndrome Respiratorio y Reproductivo Porcino/efectos de los fármacos , Enfermedades de las Aves de Corral/tratamiento farmacológico , Animales , Línea Celular , Embrión de Pollo , Pollos , Infecciones por Coronavirus/virología , Modelos Animales de Enfermedad , Células Epiteliales/virología , Humanos , Gripe Aviar/metabolismo , Gripe Aviar/virología , Gripe Humana/metabolismo , Gripe Humana/virología , Enfermedad de Newcastle/metabolismo , Enfermedad de Newcastle/virología , Síndrome Respiratorio y de la Reproducción Porcina/metabolismo , Síndrome Respiratorio y de la Reproducción Porcina/virología , Enfermedades de las Aves de Corral/virología , Porcinos
7.
Vet Microbiol ; 67(3): 221-30, 1999 Jun 30.
Artículo en Inglés | MEDLINE | ID: mdl-10418876

RESUMEN

Bovine coronavirus isolates from eight different states of the USA were compared for their antigenic properties and susceptibility to hygromycin B. Antigenic differences were observed among the isolates in a one-way hemagglutination-inhibition (HI) test using a polyclonal antiserum against the Mebus bovine coronavirus isolate. Differences were observed on isoelectric focusing among viral proteins with isoelectric points between 4.45-4.65. Most of the BCV isolates were susceptible to hygromycin B (0.5 mM) whereas a few hygromycin B resistant isolates were also found.


Asunto(s)
Enfermedades de los Bovinos/virología , Infecciones por Coronavirus/veterinaria , Coronavirus Bovino/clasificación , Animales , Anticuerpos Antivirales/biosíntesis , Bovinos , Coronavirus Bovino/química , Coronavirus Bovino/efectos de los fármacos , Pruebas de Inhibición de Hemaglutinación/veterinaria , Pruebas de Hemaglutinación/veterinaria , Humanos , Higromicina B/farmacología , Focalización Isoeléctrica/veterinaria , Ratones , Células Tumorales Cultivadas , Estados Unidos , Proteínas Virales/análisis
8.
Vet Microbiol ; 63(2-4): 147-57, 1998 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9850995

RESUMEN

Crude theaflavin was extracted from black tea and then fractionated by HPLC into five components (initial peaks (IP), TF1, TF2A, TF2B, and TF3). The crude extract and the various fractions of theaflavin were collected and tested, individually and in combination, for antirotaviral activity. The mean effective concentration (EC50) was calculated and compared. Activity varied from the most active being the uncharacterized theaflavin-like initial peaks (IP) with an EC50 of 0.125 microgram/ml to the least active being theaflavin-3 monogallate (TF2A) with an EC50 of 251.39 micrograms/ ml. The combination of TF1 + TF2A + TF2B + TF3 was more active than the sum of the activities of these four fractions individually, indicating synergism among the peaks. Only the crude extract was assayed for activity against coronavirus; the EC50 was 34.7 micrograms/ml.


Asunto(s)
Antivirales/aislamiento & purificación , Antivirales/farmacología , Biflavonoides , Catequina , Enfermedades de los Bovinos/tratamiento farmacológico , Infecciones por Coronavirus/veterinaria , Coronavirus Bovino/efectos de los fármacos , Infecciones por Rotavirus/veterinaria , Rotavirus/efectos de los fármacos , Té/química , Animales , Antivirales/química , Bovinos , Línea Celular , Quelantes/química , Quelantes/aislamiento & purificación , Quelantes/farmacología , Cromatografía Líquida de Alta Presión , Infecciones por Coronavirus/tratamiento farmacológico , Coronavirus Bovino/fisiología , Ácido Gálico/análogos & derivados , Ácido Gálico/química , Ácido Gálico/aislamiento & purificación , Ácido Gálico/farmacología , Modelos Moleculares , Conformación Molecular , Rotavirus/fisiología , Infecciones por Rotavirus/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...